Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV460: HIV DNA and Protein Vaccine with Adjuvants
NCT04826094Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Env-C Plasmid DNA and gp145 C.6980 in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Solicited Local Events Post Vaccination, Number of Solicited Systemic Events Post Vaccination and 2 more. Started Mar 2021; status: completed.
02
Drugs
Env-C Plasmid DNAgp145 C.6980
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04826094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826094.